Detalhe da pesquisa
1.
Critical Residues Involved in the Coassembly of L1 and L2 Capsid Proteins of Human Papillomavirus 16.
J Virol
; 97(3): e0181922, 2023 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36815785
2.
Rational design of a cross-type HPV vaccine through immunodominance shift guided by a cross-neutralizing antibody.
Sci Bull (Beijing)
; 69(4): 512-525, 2024 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38160175
3.
Current progress in the development of prophylactic and therapeutic vaccines.
Sci China Life Sci
; 66(4): 679-710, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36469218
4.
Characterization of an Escherichia coli-derived triple-type chimeric vaccine against human papillomavirus types 39, 68 and 70.
NPJ Vaccines
; 7(1): 134, 2022 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36316367
5.
A bacterially expressed triple-type chimeric vaccine against human papillomavirus types 51, 69, and 26.
Vaccine
; 40(42): 6141-6152, 2022 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36117002
6.
Recent Progress on the Versatility of Virus-Like Particles.
Vaccines (Basel)
; 8(1)2020 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32244935
7.
Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles.
Nat Commun
; 11(1): 2841, 2020 06 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32503989
8.
Neutralization sites of human papillomavirus-6 relate to virus attachment and entry phase in viral infection.
Emerg Microbes Infect
; 8(1): 1721-1733, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31769733